Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Aledade, Neuralink, and 370+ companies. 5-min read every Tuesday.
Value-based care company empowering independent primary care physicians to succeed in value-based contracts.
| Industry | Healthcare Technology |
| Stage | Series F |
| IPO Status | Pre-IPO |
| Valuation | $3.5B |
| Total Funding | $660M |
| Headquarters | Bethesda, MD |
Brain-computer interface company developing implantable chips (Telepathy device). Raised $650M Series E at $9B valuation (June 2025). CEO Elon Musk has no IPO plans — company is focused on FDA clinical trials, not public markets.
| Industry | Healthcare Technology |
| Stage | Series H |
| IPO Status | Private |
| Valuation | $35.0B |
| Total Funding | $5.0B |
| Headquarters | Austin, TX |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Aledade is valued at $3.5B. Neuralink is valued at $35.0B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Aledade is currently pre-IPO. Neuralink is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Aledade has raised $660M. Neuralink has raised $5.0B.
Aledade operates in Healthcare Technology, while Neuralink operates in Healthcare Technology.
Aledade is a Healthcare Technology company valued at $3.5B with $660M raised. Neuralink is a Healthcare Technology company valued at $35.0B with $5.0B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Aledade and Neuralink through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.